Welcome to our dedicated page for QRONS news (Ticker: QRON), a resource for investors and traders seeking the latest updates and insights on QRONS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QRONS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QRONS's position in the market.
Qrons Inc. (OTCQB:QRON) announced that the USPTO granted U.S. Patent No. 10,954,315 to Dartmouth College, covering 3-D printing materials. This patent results from Qrons' collaboration with Professor Chenfeng Ke since July 2018, focused on developing 3D printable hydrogels for its stem cell-based treatments for traumatic brain injuries. The exclusive license from Dartmouth allows Qrons to leverage these advancements in its biotech innovations. CEO Jonah Meer emphasized the importance of this step in enhancing Qrons' technological foundation.
Qrons Inc. (OTCQB:QRON) has launched a newly redesigned website aimed at enhancing public education on its expanded focus in treating neuronal diseases beyond traumatic brain injury (TBI). The website reflects Qrons' synergy of tissue engineering, stem cells, and machine learning technologies. CEO Jonah Meer expressed enthusiasm over leveraging proprietary knowledge and collaboration with Israeli biotech ventures. The new site will enable more flexible updates for future developments and reflects the company's commitment to innovative biotechnology solutions.